Sun Pharma Secures Global Rights for Lerodalcibep (PCSK9 Inhibitor) Ex-US/China; EU Approves Lyrokaul
Sun Pharma has entered a global licensing agreement with LIB Therapeutics for lerodalcibep (PCSK9 inhibitor), excluding the US and China. Lyrokaul (lerodalcibep) received EU approval on Sept 21, 2026. This deal grants Sun Pharma access to a US$3.7 billion market ex-US/China, growing at 38% CAGR.
The agreement provides Sun Pharma with rights to a drug in a significant and fast-growing market (US$3.7 billion ex-US/China, 38% CAGR), which is expected to substantially boost its Innovative Medicines portfolio and future revenue.
The announcement details a significant global licensing agreement for a promising drug, EU approval, and access to a large, growing market, which is positive for the company's growth and portfolio.
Sun Pharmaceutical Industries Limited (Sun Pharma) and LIB Therapeutics Inc. have announced a global licensing, commercialization, and manufacturing agreement for lerodalcibep, a PCSK9 inhibitor. This agreement grants Sun Pharma exclusive rights to commercialize and manufacture lerodalcibep worldwide, excluding the United States and China.
Lerodalcibep, to be marketed as Lyrokaul in the EU, received EU approval on September 21, 2026, for lowering LDL-C and offers a once-monthly dosing regimen with six-month ambient storage. This partnership is poised to strengthen Sun Pharma's Innovative Medicines portfolio by providing access to the significant ex-US and China PCSK9 market, valued at US$3.7 billion and growing at a 38% CAGR. The global PCSK9 market is projected to approach US$7 billion in 2026.
Under the agreement terms, LIB Therapeutics will receive an upfront payment, future milestone payments, and royalties based on net sales in the licensed territories. Sun Pharma will manage regulatory approvals in territories where approval has not yet been obtained. Kirti W. Ganorkar, Managing Director of Sun Pharma, highlighted the convenience of the once-monthly dosing and the significant step in strengthening the company's global innovative medicines portfolio. Evan Stein, MD, PhD, Chief Operating and Scientific Officer of LIB Therapeutics, expressed enthusiasm for partnering with Sun Pharma to bring lerodalcibep to more patients globally.
What to do with a filing like this
Sun Pharmaceutical Industries Limited filed this with the NSE as a statutory disclosure, categorised under acquisition. It is a primary document, not a recommendation, and the desk marks it high impact, which is the band that most often changes something.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Sun Pharmaceutical Industries Limited. Read the original for the full detail.